Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs

Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.

Source: CNBC

Continue reading...